Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 3099Neoplasms 2443Carcinoma, Non-Small-Cell Lung 1867Prostatic Neoplasms 1619Colorectal Neoplasms 1426Lung Neoplasms 1295Multiple Myeloma 929Neoplasm Metastasis 920Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 848Ovarian Neoplasms 799Melanoma 784Carcinoma, Hepatocellular 737Stomach Neoplasms 639Brain Neoplasms 636Recurrence 633Squamous Cell Carcinoma of Head and Neck 632Head and Neck Neoplasms 609Glioblastoma 567Lymphoma 540Uterine Cervical Neoplasms 539Triple Negative Breast Neoplasms 505Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 499Hematologic Neoplasms 463Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 442Lymphoma, Non-Hodgkin 436Sarcoma 434

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Proteostasis Deficiencies × 1 year × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡